La référence en hépatite C au Québec depuis 2003

Great news in hep C treatment, EPCLUSA the first pangenotypic approved in Quebec

Published by CAPAHC on

20/03/2017

After a long waiting for, and hard discussions about pricing, we are now pleased to have the first pangenotypic (for all genotypes) approved in Quebec.

This access to treatments is now expanded to a broader population of hepatitis C patients in our province.

Without ribavirine for genotypes 2 et 3, one pill for 12 weeks (24 weeks for patient with decompensated cirrhosis), no bad side effects (headache and fatigue).

We definitively are on the track for hep C elimination….

Laurence Mersilian

EPCLUSA™, to treat all six genotypes of chronic hepatitis C infection, added to the Liste des médicaments de la RAMQ (CNW Group/Gilead Sciences, Inc.)http://www.newswire.ca/news-releases/epclusa-to-treat-all-six-genotypes-of-chronic-hepatitis-c-infection-added-to-the-liste-des-medicaments-de-la-ramq-616628064.html

Categories: English

Related Posts

English

Hepatitis B: Frequently Asked Questions

What’s Hepatitis B? Hepatitis B is a serious liver infection caused by the HBV (hepatitis B virus). The transmission of the HBV can happen during sexual contact (vaginal, anal or oral), through infected blood or Read more…

English

Urgent steps needed to accelerate diagnosis of hepatitis-C

Rawalpindi : Having one of the highest prevalence rate of hepatitis-C in the world, Pakistan needs to work religiously both for treatment of patients and for screening of people if we want to eliminate the Read more…

English

Hepatitis C Treatments, 2 new products

Here are two new medicines that have just been approved by Health Canada on August 17th and offer more therapeutic options for treating physicians, depending on the specific case of each patient.